FindTrial
Sign In

Clinical study of Combined action of Icotinib and brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis

Clinical study of Combined action of Icotinib and brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17012099
Enrollment
Unknown
Registered
2017-07-23
Start date
2017-06-30
Completion date
Unknown
Last updated
2017-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Case series:Icotinib and brain radiotherapy

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) patient confirmed NSCLS; 2) MRI indicated that the measurable brain metastasis lesion; 3) patient with EGFR mutations; 4) aged 18 ~ 75 years old;ECOG PS 0 ~ 2 points;Life expectancy > 3 months; 5) all subjects or their guardians must sign the subject informed consent before entering the test.

Exclusion criteria

Exclusion criteria: 1) intracranial pressure causes vomiting; 2) severe liver, kidney and lung injury; 3) allergic to Icotinib; 4) only with meningeal metastases.

Design outcomes

Primary

MeasureTime frame
intracranial Progression free survival;systemic Progression free survival;Overall survival;—

Contacts

Public ContactYu Li

The Second Hospital of ShanDong University

qlliyu@163.com+86 18560082770

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026